Literature DB >> 11166828

In vitro topo II--DNA complex accumulation and cytotoxicity of etoposide in leukaemic cells from patients with acute myelogenous and chronic lymphocytic leukaemia.

Y Wang1, R Zhou, J Liliemark, A Gruber, S Lindemalm, F Albertioni, E Liliemark.   

Abstract

Topoisomerase II (topo II) is the target enzyme of etoposide, and DNA--topo II complex accumulation is considered crucial for the cytotoxic effect. We used a SDS--KCl precipitation assay to determine the complex accumulation induced by etoposide in leukaemic cells isolated from 58 patients, 31 with acute myelogenous leukaemia (AML), and 27 with chronic lymphocytic leukaemia (CLL). To investigate whether the sensitivity towards etoposide was dependent on the complex accumulation in the cells, we investigated the drug-induced DNA damage using a DNA unwinding assay and the in vitro cytotoxicity of etoposide using the MTT assay. AML cells had higher complex accumulation (P=0.006) and more DNA damage (P=0.029) compared with CLL cells. The data support a relationship between etoposide-induced complex accumulation and DNA damage in leukaemic cells from AML and CLL patients. However, the induced DNA damage did not translate to in vitro cytotoxicity, suggesting that other factors, such as DNA repair and apoptosis functions, also play important roles to determine the etoposide sensitivity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11166828     DOI: 10.1016/s0145-2126(00)00103-x

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  2 in total

Review 1.  Mitochondrial metabolism as a target for acute myeloid leukemia treatment.

Authors:  Svetlana B Panina; Jingqi Pei; Natalia V Kirienko
Journal:  Cancer Metab       Date:  2021-04-21

2.  Nitric oxide inhibits topoisomerase II activity and induces resistance to topoisomerase II-poisons in human tumor cells.

Authors:  Ashutosh Kumar; Marilyn Ehrenshaft; Erik J Tokar; Ronald P Mason; Birandra K Sinha
Journal:  Biochim Biophys Acta       Date:  2016-04-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.